KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Change in Working Capital Change in Working Capital Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Teva Pharmaceutical Industries (TEVA) Free Cash Flow (2016 - 2026)

Teva Pharmaceutical Industries filings provide 18 years of Free Cash Flow readings, the most recent being -$208.0 million for Q1 2026.

On a quarterly basis, Free Cash Flow rose 10.34% to -$208.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $1.2 billion, a 53.2% increase, with the full-year FY2025 number at $1.1 billion, up 53.27% from a year prior.
Free Cash Flow hit -$208.0 million in Q1 2026 for Teva Pharmaceutical Industries, down from $1.0 billion in the prior quarter.
In the past five years, Free Cash Flow ranged from a high of $1.1 billion in Q4 2023 to a low of -$284.0 million in Q1 2023.
Median Free Cash Flow over the past 5 years was $131.0 million (2025), compared with a mean of $210.2 million.
The widest YoY moves for Free Cash Flow: up 5225.0% in 2023, down 134.2% in 2023.
Teva Pharmaceutical Industries' Free Cash Flow stood at $831.0 million in 2022, then increased by 28.16% to $1.1 billion in 2023, then plummeted by 58.12% to $446.0 million in 2024, then surged by 127.8% to $1.0 billion in 2025, then plummeted by 120.47% to -$208.0 million in 2026.
The last three reported values for Free Cash Flow were -$208.0 million (Q1 2026), $1.0 billion (Q4 2025), and $233.0 million (Q3 2025) per Business Quant data.